Magnetic resonance spectroscopy in mild cognitive impairment: Systematic review and meta-analysis

Research using proton magnetic resonance spectroscopy (MRS) can potentially elucidate metabolite changes representing early degeneration in Mild Cognitive Impairment (MCI), an early stage of dementia. We integrated the published literature using meta-analysis to identify patterns of metabolite changes in MCI. 29 MRS studies (with a total of 607 MCI patients and 862 healthy controls) were classified according to brain regions. Hedges' g was used as effect size in a random effects model. N-Acetyl Aspartate (NAA) measures were consistently reduced in posterior cingulate (PC), hippocampus, and the paratrigonal white matter (PWM). Creatine (Cr) concentration was reduced in the hippocampus and PWM. Choline (Cho) concentration was reduced in the hippocampus while Cho/Cr ratio was raised in the PC. Myo-inositol (mI) concentration was raised in the PC and mI/Cr ratio was raised in the hippocampus. NAA/mI ratio was reduced in the PC. NAA may be the most reliable marker of brain dysfunction in MCI though mI, Cho, and Cr may also contribute towards this.

[1]  N. Fayed,et al.  Changes in Metabolite Ratios after Treatment with Rivastigmine in Alzheimer’s Disease , 2006, CNS drugs.

[2]  J. Moffett,et al.  N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology , 2007, Progress in Neurobiology.

[3]  F Träber,et al.  A multicenter 1H-MRS study of the medial temporal lobe in AD and MCI , 2009, Neurology.

[4]  Stephen J Senn,et al.  Overstating the evidence – double counting in meta-analysis and related problems , 2009, BMC Medical Research Methodology.

[5]  D J Jenden,et al.  In vivo 1H MRS choline: correlation with in vitro chemistry/histology. , 1996, Life sciences.

[6]  R. Prost,et al.  Proton Magnetic Resonance Spectroscopy of the Hippocampus in Patients With Mild Cognitive Impairment: A Pilot Study , 2007, Journal of computer assisted tomography.

[7]  E. Barbeau,et al.  Impaired visual recognition memory in amnestic mild cognitive impairment is associated with mesiotemporal metabolic changes on magnetic resonance spectroscopic imaging. , 2011, Journal of Alzheimer's disease : JAD.

[8]  A. Marmarou,et al.  N-Acetylaspartate reduction as a measure of injury severity and mitochondrial dysfunction following diffuse traumatic brain injury. , 2001, Journal of neurotrauma.

[9]  R. Wu,et al.  Quantitative multivoxel proton MR spectroscopy study of brain metabolites in patients with amnestic mild cognitive impairment: a pilot study , 2012, Neuroradiology.

[10]  J. Molinuevo,et al.  Naming Is Associated with Left Temporal Pole Metabolite Levels in Neurodegenerative Diseases , 2008, Dementia and Geriatric Cognitive Disorders.

[11]  J Philip Miller,et al.  Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI , 2006, Neurology.

[12]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[13]  Patrizia Mecocci,et al.  Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy , 2006, Neurobiology of Aging.

[14]  Xin Yu,et al.  Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. , 2003, The American journal of psychiatry.

[15]  Peter Schönknecht,et al.  Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young-old subjects. , 2005, The American journal of psychiatry.

[16]  Kuncheng Li,et al.  Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and alzheimer disease , 2009, Acta radiologica.

[17]  Tao Wang,et al.  Using proton magnetic resonance spectroscopy to identify mild cognitive impairment , 2011, International Psychogeriatrics.

[18]  J. Frahm,et al.  Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS , 1998, Magnetic resonance in medicine.

[19]  Jong Hun Kim,et al.  Neurochemical alterations of the entorhinal cortex in amnestic mild cognitive impairment (aMCI): a three-year follow-up study. , 2012, Archives of gerontology and geriatrics.

[20]  J. Molinuevo,et al.  Longitudinal Study of Amnesic Patients at High Risk for Alzheimer’s Disease: Clinical, Neuropsychological and Magnetic Resonance Spectroscopy Features , 2007, Dementia and Geriatric Cognitive Disorders.

[21]  Qing Tian,et al.  Correlation between Choline Signal Intensity and Acetylcholine Level in Different Brain Regions of Rat , 2008, Neurochemical Research.

[22]  J. O'Brien,et al.  PET imaging of brain amyloid in dementia: a review , 2011, International journal of geriatric psychiatry.

[23]  K. Kantarci.  1H magnetic resonance spectroscopy in dementia. , 2007, The British journal of radiology.

[24]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[25]  I. Akiguchi,et al.  Hippocampal metabolites and memory performances in patients with amnestic mild cognitive impairment and Alzheimer’s disease , 2012, Neurobiology of Learning and Memory.

[26]  B. Winblad,et al.  Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[27]  Giuseppe Scotti,et al.  A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment , 2005, NeuroImage.

[28]  C. Jack,et al.  Mild cognitive impairment: ten years later. , 2009, Archives of neurology.

[29]  Claudius Mueller,et al.  Longitudinal Metabolic and Cognitive Changes in Mild Cognitive Impairment Patients , 2008, Alzheimer disease and associated disorders.

[30]  N. Fayed,et al.  Brain Glutamate Levels Are Decreased in Alzheimer’s Disease , 2011, American journal of Alzheimer's disease and other dementias.

[31]  Jacob Cohen,et al.  A power primer. , 1992, Psychological bulletin.

[32]  E. Tangalos,et al.  Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. , 2006, Archives of neurology.

[33]  C. Jack,et al.  Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. , 2008, Radiology.

[34]  Rolf Gruetter,et al.  The neurochemical profile quantified by in vivo 1H NMR spectroscopy , 2012, NeuroImage.

[35]  Ranjan Duara,et al.  Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. , 2011, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[36]  I. Akiguchi,et al.  Absolute Quantification in Proton Magnetic Resonance Spectroscopy Is Useful to Differentiate Amnesic Mild Cognitive Impairment from Alzheimer’s Disease and Healthy Aging , 2010, Dementia and Geriatric Cognitive Disorders.

[37]  M. Albert,et al.  Amnestic MCI or prodromal Alzheimer's disease? , 2004, The Lancet Neurology.

[38]  Roland Kreis,et al.  Development of the human brain: In vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy , 1993, Magnetic resonance in medicine.

[39]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[40]  H. Arrighi,et al.  Mild cognitive impairment: Disparity of incidence and prevalence estimates , 2012, Alzheimer's & Dementia.

[41]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[42]  E G Tangalos,et al.  Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease , 2000, Neurology.

[43]  J. Bond,et al.  Two‐Year Progression from Mild Cognitive Impairment to Dementia: To What Extent Do Different Definitions Agree? , 2008, Journal of the American Geriatrics Society.

[44]  C. Navarro,et al.  Magnetic Resonance Spectroscopy Performance for Detection of Dementia, Alzheimer’s Disease and Mild Cognitive Impairment in a Community-Based Survey , 2008, Dementia and Geriatric Cognitive Disorders.

[45]  S. Moon,et al.  Functional Investigation of Bilateral Posterior Cingulate Gyri Using Multivoxel MR Spectroscopy , 2012, European Neurology.

[46]  N. Fayed,et al.  Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. , 2005, The American journal of psychiatry.

[47]  J. Molinuevo,et al.  Cortical Brain Metabolism as Measured by Proton Spectroscopy Is Related to Memory Performance in Patients with Amnestic Mild Cognitive Impairment and Alzheimer’s Disease , 2007, Dementia and Geriatric Cognitive Disorders.

[48]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[49]  I. Akiguchi,et al.  Absolute Quantification in Proton Magnetic Resonance Spectroscopy Is Superior to Relative Ratio to Discriminate Alzheimer’s Disease from Binswanger’s Disease , 2008, Dementia and Geriatric Cognitive Disorders.

[50]  C. Jack,et al.  Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. , 2003, AJNR. American journal of neuroradiology.

[51]  N. Schuff,et al.  Regional Myo-inositol Concentration in Mild Cognitive Impairment Using 1H Magnetic Resonance Spectroscopic Imaging , 2009, Alzheimer disease and associated disorders.

[52]  N. Fayed,et al.  Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: a prospective cohort study , 2011, BMJ Open.

[53]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[54]  P. Matthews,et al.  Reversible decreases in N‐acetylaspartate after acute brain injury , 1995, Magnetic resonance in medicine.

[55]  N. Schuff,et al.  Evidence of neurodegeneration in brains of older adults who do not yet fulfill MCI criteria , 2010, Neurobiology of Aging.

[56]  F. Träber,et al.  In-vivo proton MR-spectroscopy of the human brain: Assessment of N-acetylaspartate (NAA) reduction as a marker for neurodegeneration , 2002, Amino Acids.

[57]  J. Fisk,et al.  Outcomes of incident mild cognitive impairment in relation to case definition , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[58]  Jerzy Leszek,et al.  Multimodal imaging in diagnosis of Alzheimer's disease and amnestic mild cognitive impairment: value of magnetic resonance spectroscopy, perfusion, and diffusion tensor imaging of the posterior cingulate region. , 2011, Journal of Alzheimer's disease : JAD.

[59]  J J Mallet,et al.  Regional differences and metabolic changes in normal aging of the human brain: proton MR spectroscopic imaging study. , 2001, AJNR. American journal of neuroradiology.

[60]  Shigehiro Morikawa,et al.  The Profile of Hippocampal Metabolites Differs between Alzheimer's Disease and Subcortical Ischemic Vascular Dementia, as Measured by Proton Magnetic Resonance Spectroscopy , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[61]  Heinrich Lanfermann,et al.  Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy , 2009, Psychiatry Research: Neuroimaging.

[62]  Bing Zhang,et al.  Evaluation of functional MRI markers in mild cognitive impairment , 2009, Journal of Clinical Neuroscience.

[63]  W. Markesbery,et al.  Neuropathologic alterations in mild cognitive impairment: a review. , 2010, Journal of Alzheimer's disease : JAD.

[64]  J. Moll,et al.  Contribution of 1H Spectroscopy to a Brief Cognitive-Functional Test Battery for the Diagnosis of Mild Alzheimer’s Disease , 2012, Dementia and Geriatric Cognitive Disorders.

[65]  E. Tangalos,et al.  Comparative Diagnostic Utility of Different MR Modalities in Mild Cognitive Impairment and Alzheimer’s Disease , 2002, Dementia and Geriatric Cognitive Disorders.

[66]  Jeffry R Alger,et al.  Quantitative Proton Magnetic Resonance Spectroscopy and Spectroscopic Imaging of the Brain: A Didactic Review , 2010, Topics in magnetic resonance imaging : TMRI.

[67]  M. Barcikowska,et al.  N-acetylaspartate, choline, myoinositol, glutamine and glutamate (glx) concentration changes in proton MR spectroscopy (1H MRS) in patients with mild cognitive impairment (MCI) , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[68]  Clifford R Jack,et al.  1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease , 2002, Journal of the International Neuropsychological Society.

[69]  F. Jessen,et al.  Treatment monitoring and response prediction with proton MR spectroscopy in AD , 2006, Neurology.

[70]  E. Zamrini,et al.  Elevated brain scyllo‐inositol concentrations in patients with Alzheimer's disease , 2007, NMR in biomedicine.

[71]  C. Jack,et al.  Risk of dementia in MCI , 2009, Neurology.

[72]  J. Klein.  Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids , 2000, Journal of Neural Transmission.

[73]  Clifford R. Jack,et al.  Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease , 2007, Neurobiology of Aging.

[74]  R. Bartha,et al.  Reduced hippocampal glutamate in Alzheimer disease , 2011, Neurobiology of Aging.

[75]  D. Auer,et al.  Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease , 2005, Neuroscience Letters.

[76]  Stephen K Fisher,et al.  Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance , 2002, Journal of neurochemistry.

[77]  O. Okonkwo,et al.  Executive function is associated with brain proton magnetic resonance spectroscopy in amnestic mild cognitive impairment , 2007, Journal of clinical and experimental neuropsychology.

[78]  S. Chantal,et al.  Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease , 2004, Brain Research.

[79]  E. Reiman,et al.  Vascular risk factors, incidence of MCI, and rates of progression to dementia , 2004, Neurology.

[80]  P. Barker,et al.  MR spectroscopy and spectroscopic imaging of the brain. , 2011, Methods in molecular biology.

[81]  Joanne Wuu,et al.  Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. , 2003, Journal of Alzheimer's disease : JAD.

[82]  U Senin,et al.  1H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging , 2001, Neuroreport.

[83]  W. Jagust,et al.  Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo , 2009, Behavioural neurology.

[84]  Huadong Zhou,et al.  Correlation of auditory event-related potentials and magnetic resonance spectroscopy measures in mild cognitive impairment , 2010, Brain Research.

[85]  Hyun Young Lee,et al.  Metabolite Investigation in Both Anterior and Posterior Cingulate Gyri in Alzheimer’s Disease Spectrum Using 3-Tesla MR Spectroscopy , 2012, Dementia and Geriatric Cognitive Disorders.

[86]  S. DeKosky,et al.  Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease , 2011, Neurology.

[87]  D. G. Clark,et al.  Brain Metabolic Correlates of Decision Making in Amnestic Mild Cognitive Impairment , 2010, Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition.

[88]  N. Fayed,et al.  Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. , 2008, Academic radiology.

[89]  Jennifer L. Whitwell,et al.  Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. , 2008, Archives of neurology.

[90]  Saadallah Ramadan,et al.  Neurospectroscopy: the past, present and future. , 2010, Chemical reviews.

[91]  K. Ritchie.  Mild cognitive impairment: an epidemiological perspective , 2004, Dialogues in clinical neuroscience.

[92]  Oded Gonen,et al.  Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. , 2003, Magnetic resonance imaging.

[93]  Declan G. M. Murphy,et al.  Hippocampal Proton MR Spectroscopy in Early Alzheimer’s Disease and Mild Cognitive Impairment , 2011, Brain Topography.